Tonix2.jpg
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
September 13, 2021 08:00 ET | Tonix Pharmaceuticals Holding Corp.
TNX-1800 is a Live Virus Vaccine Designed to Elicit Durable T cell Immunity TNX-1800 is a Modified Version of Dr. Edward Jenner’s Vaccine that Eradicated Smallpox, Engineered to Express SARS-CoV-2...
Tonix2.jpg
Tonix Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
September 07, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix2.jpg
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
August 24, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
Company Plans to Submit an IND to Support a Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with...
Tonix2.jpg
Tonix Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
August 09, 2021 16:45 ET | Tonix Pharmaceuticals Holding Corp.
Central Nervous System Pipeline Progressing with Two Phase 2 Studies (TNX-1300 and TNX-1900) and One Phase 3 Study (TNX-102 SL) Expected to Start This Year COVID-19 Pipeline Progressing with...
Tonix2.jpg
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
August 02, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a...
Tonix2.jpg
Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs
July 27, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
R&D Facility in Frederick, MD is Expected to Provide Internal Capacity to Discover and Develop Vaccines and Antiviral Drugs Against COVID-19, its Variants and Other Infectious Diseases Facility,...
Tonix2.jpg
Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
July 23, 2021 16:40 ET | Tonix Pharmaceuticals Holding Corp.
RALLY Study Will Stop Enrolling New Participants Following Recommendation from an Interim Analysis Indicating Inadequate Separation from Placebo at Week-14 in the First 50% of Participants, Based on...
Tonix2.jpg
Tonix Pharmaceuticals Announces New Board Member, Carolyn E. Taylor
July 19, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn E....
Tonix2.jpg
Tonix Pharmaceuticals Added to Russell 2000® and Russell 3000® Indexes
June 28, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tonix was...
Tonix2.jpg
Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)
June 21, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development Condition Afflicts More Than 30...